VitaDAO 2024 Highlights

High-Level KPIs*

• Treasury: $42M (411% YoY growth)

• Token Holders: total of 8,500+ across all blockchains (250% YoY growth)

• Re-org success: monthly burn rate dropped 50% from ~$100k to ~$50k

*as of December 2024

Scientific Updates

VitaDAO's projects showed promising developments towards medicines that could slow or reverse aging by reprogramming aged cells, removing toxic aging cells, and treating other age-related conditions:

• AB4AD - Successfully identified and validated 31 proteins that showed significant immune response in AD patients or controls. Some of them are preferentially targeted in Alzheimer's patients, while others may show a stronger reaction in old cognitively-intact individuals.

• Etheros Pharma in-vivo testing confirmed a large therapeutic window for their lead molecule, and has succeeded in creating a number of new compounds for potential new applications.

• The Exercise & Rapamycin clinical trial co-funded by VitaDAO under the leadership of Dr Stanfield has completed the data collection phase. Data analysis will start shortly and results should be published in a few months. Protocol available here.

• Mantis Photonics tested their hyperspectral ocular imaging technology in a small clinical trial with 57 people, obtaining 93% accuracy in diagnosing Alzheimer’s. These results will be published soon.

• Oisin Bio published a paper on the safe and effective in vivo delivery of DNA and RNA using their proteolipid vehicles in collaboration with Entos.

• Remedium Bio published preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™ in a paper on the Gene journal.

• Vita-FAST went through two iterations of lead series reaching nanomolar potency at inducing autophagy.

• VitaRNA successfully identified from a series of candidate oligos a promising lead oligo and validated it in combination with an AAV. The project is currently raising $1M in a follow-on crowdsale for drug formulation and testing in animal models.

Business updates

• Cyclarity Therapeutics announced the closing of the first tranche of its Series A funding round, led by Ki Tua Fund LP and Starbloom Primrose LP. They will use the funds to commence clinical trials or the development of UDP-003, a novel therapeutic designed to reduce atherosclerotic plaque accumulation.

• HDAX Therapeutics raised a $3.2M seed round for developing HDAC6 inhibitors with blood-brain barrier penetration capabilities.

• The Longevity Hackers Movie co-funded by VitaDAO has completed production and is now available in VOD on Apple TV, Prime Video, Google Play, Vudu, and soon on Fandango. More information here.

• Oisín Biotechnologies announces